HPR2 Baseline Characteristics of Patients Applying for Reimbursment of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1321
https://www.valueinhealthjournal.com/article/S1098-3015(23)04451-0/fulltext
Title :
HPR2 Baseline Characteristics of Patients Applying for Reimbursment of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04451-0&doi=10.1016/j.jval.2023.09.1321
First page :
Section Title :
Open access? :
No
Section Order :
10796